Shares of dialysis provider DaVita Inc. (NYSE:DVA)
jumped 25.3% in the morning session after the company reported fourth-quarter results that topped Wall Street's expectations and issued a robust earnings forecast for 2026.
Dialysis provider DaVita Inc. (NYSE:DVA) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 9.9% year on year to $3.62 billion. Its non-GAAP profit of $3.40 per share was 6.5% above analysts’ consensus estimates.
Dialysis provider DaVita Inc. (NYSE:DVA) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 9.9% year on year to $3.62 billion. Its non-GAAP profit of $3.40 per share was 6.5% above analysts’ consensus estimates.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns
as healthcare stocks have gained 17.4% over the past six months while the S&P 500 was up 9.6%.
Date: January 28, 2026 The landscape of American managed care is currently undergoing a seismic shift, and perhaps no company exemplifies this transformation—and the accompanying volatility—more than Humana Inc. (NYSE: HUM). Long considered the "pure-play" leader in Medicare Advantage (MA), Humana finds itself at a critical juncture. As of today, January 28, 2026, the company [...]
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
